anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For all studies, participants will be recruited via paper and electronic flyers on campus and in the surrounding communities. Interested participants will be screened via phone, email and/or web form to assess eligibility according to criteria listed elsewhere. Should participants qualify, they will be invited to complete a single laboratory session at the Intermountain Neuroimaging Facility at CU Boulder. Participants will be sent a copy of the consent form to read in advance of their visit, and to keep for their records.

Once arriving at the laboratory, participants will complete the consent process, in which a research assistant trained in ethical principles regarding human subjects research will answer any questions about the consent form and verbally reinforce the key rights of the participants outlined there. Once both parties are satisfied, consent forms will be signed.

Participants will then complete a mandatory day-of MRI eligibility form to ensure scanner compatibility has not changed since the initial screening (done by phone, email or webform). Females who are unable to indicate "no" to the question, "is it possible that you are pregnant?" will be asked to take a pregnancy test provided at the MR facility. Participants will change into MRI- compatible clothes or scrubs. Participants will sit with a trained research assistant/experimenter who will give an overview of the entire session, and then begin training for the cognitive reappraisal task. This training takes 10-15 minutes. During the training, the experimenter will offer several possible reappraisals of negative images and allow the participants to offer their own as well, providing encouragement and feedback. During this training, the experimenter will also go over the method of encouragement and feedback. During this training, the experimenter will also go over the method of responding (using an external button box). Participants will be reminded during training that they may stop the experiment at any point if the pictures are too upsetting.

Immediately following task training, participants will make a general mood rating using the PANAS. Then, participants will be screened one final time for metal in or near their bodies at the door to the shielded MRI room, then be placed in the MRI scanner by a certified, full-time MRI technician. Participants will be reminded they can stop the experiment at any point if they are physically uncomfortable or become claustrophobic, and will be outfitted with a panic button to indicate that they wish to stop the experiment immediately once it has begun. After the initial structural and calibration scans, participants will complete the reappraisal task. The task will take 40-50 minutes (broken up into 4-5 separate functional runs in the scanner, with each run taking around 10 minutes).
Fibrosis results in one-third of all deaths globally and is a major healthcare challenge. Fibrosis is scarring caused by the excess deposition of extracellular matrix proteins by fibroblasts. Inhibition of pathways downstream of transforming growth factor β (TGF-β) a pluripotent growth factor, has potent antifibrotic effects in different organs. Here we show that loss of bone morphogenetic protein (BMP-3) is a feature of kidney fibrosis, independent of the initiating injury, suggesting loss of this cytokine is a core fibrotic mechanism. TGF-β decreased BMP3 expression in human fibroblasts is possibly a feed-forward loop that contributes to increased and sustained TGF-β activity. Recombinant human BMP-3 reduced TGF-β induced fibroblast contraction, migration and invasion, pathways that lead to scarring and tissue stiffening. BMP-3 reduced TGF-β stimulated collagen cross-linking, and Ox-LDL receptor 1, a regulator of collagen deposition. BMP-3 inhibited TGF-β stimulated lysyl oxidase activity. Lysyl oxidase mediated collagen cross-linking is a critical process in TGF-β induced fibrosis. We propose that BMP-3 alters fibroblast responses to TGF-β, shifting the balance from fibrosis to repair. Recombinant human BMP-3 shows promise for development as a novel therapeutic for fibrosis.
Plants are frequently attacked by a variety of pathogens and thus have evolved a series of defense mechanisms, one important mechanism is resistance gene (R gene)-mediated disease resistance, but its expression is tightly regulated. NBS-LRR genes are the largest gene family of R genes. microRNAs (miRNAs) target to a number of NBS-LRR genes and trigger the production of phased small interfering RNAs (phasiRNAs) from these transcripts. phasiRNAs cis or trans regulate NBS-LRR genes, which can result in the repression of R gene expression. In this study, we screened for upregulated miR482 in the susceptible apple cultivar 'Golden Delicious' (GD) after inoculation with the fungal pathogen Alternaria alternata f. sp. mali (ALT1). Additionally, through combined degradome sequencing, we identified a gene targeted by miR482, named MdTNL1, a gene encoding a TIR-NBS-LRR (Toll/interleukin1 receptor-nucleotide binding site-leucine-rich repeat) protein. This gene exhibited a significant down-regulation post ALT1 inoculation, suggesting an impact on gene expression mediated by miRNA regulation. miR482 could cleave MdTNL1 and generate phasiRNAs at the cleavage site. We found that overexpression of miR482 inhibited the expression of MdTNL1 and thus reduced the disease resistance of GD, while silencing of miR482 increased the expression of MdTNL1 and thus improved the disease resistance of GD. This work elucidates key mechanisms underlying the immune response to Alternaria infection in apple. Identification of the resistance genes involved will enable molecular breeding for prevention and control of Alternaria leaf spot disease in this important fruit crop.
The invention provides a feed additive for veterinary drug solid fermentation and a preparation method of the feed additive. The feed additive comprises the following components by weight percentage: 15-30% of fiveleaf gynostemma herb, 20-30% of caulis lonicerae, 10-20% of biological enzyme, 8-15% of probiotic liquid, and 5-47% of galactooligosaccharide. Solid fermentation methods of the fiveleaf gynostemma herb and the caulis lonicerae are simple and easy, and large-scale production can be achieved easily. According to the feed additive and the preparation method, fermentation products comprise dregs and fermentation liquid that can be added to feed or drinking water, and no waste or pollution arising from residual substrates is caused. The fermentation products are good in stability, special in fragrance and better in palatability. The adopted fiveleaf gynostemma herb and the caulis lonicerae have wider resource distribution in China, are easy to obtain, and synergize with each other to exert effects of adjusting immunity and intestinal environments, and clearing away heat and toxic materials.
Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach \>90% of their maximal heart rate.
The present invention provides novel Lactococcus sp. having blood cholesterol-lowering activity, or the like. According to the present invention, a specific Lactococcus sp. strain has excellent acid resistance and biliary resistance, whereby most of them may reach the intestines when oral administration to a human body. In addition, reproduction of harmful bacteria in the intestines is effectively suppressed or a blood cholesterol level is reduced. Moreover, since food safety is excellent, a specific Lactococcus sp. strain is useful as a probiotic material. In addition, the specific Lactococcus sp. strain according to the present invention ferments rice bran to increase the antioxidant activity of the rice bran or the content of an active ingredient contained in the rice bran. Therefore, the fermented product or an extract thereof may be used as a food and drug material or a cosmetic material used for preventing, improving, and treating aging by oxidation, a disease caused by oxidation reaction, and the like.
Administer XYWAV at least 2 hours after eating [see Clinical Pharmacology (12.3)]. Prepare all doses of XYWAV prior to bedtime. Prior to ingestion, each dose of XYWAV should be diluted with approximately ¼ cup (approximately 60 mL) of water in the empty pharmacy-provided containers. Solutions prepared following dilution should be consumed within 24 hours.

Patients should take each dose of XYWAV while in bed and lie down immediately after dosing, and remain in bed following ingestion of each dose. XYWAV may cause patients to fall asleep abruptly without first feeling drowsy [see Adverse Reactions (6.2)]. 

Patients will often fall asleep within 5 minutes of taking XYWAV, and will usually fall asleep within 15 minutes, though the time it takes any individual patient to fall asleep may vary from night to night.

If dosing twice nightly, patients may need to set an alarm to awaken for the second dose. If the second dose is missed, that dose should be skipped and XYWAV should not be taken again until the next night. Two XYWAV doses should never be taken at one time.
BREYNA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. BREYNA has not been studied in patients with acutely deteriorating asthma or COPD. The initiation of BREYNA in this setting is not appropriate. 

Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of BREYNA with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of BREYNA. 

BREYNA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta2-agonist, not BREYNA, should be used to relieve acute symptoms such as shortness of breath.

When beginning treatment with BREYNA, patients who have been taking oral or inhaled, short- acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
BACKGROUND: The impact of cirrhosis on the postoperative outcomes of distal pancreatectomy is yet to be reported. We aimed to evaluate the outcomes of distal pancreatectomy in patients with cirrhosis.
METHODS: We conducted a retrospective, multicentric study patients with cirrhosis who underwent planned distal pancreatectomy between 2008 and 2020 in French high volume centers. Patients with cirrhosis were matched 1:4 for demographic, surgical, and histologic criteria with patients without cirrhosis. The primary endpoint was severe morbidity (Clavien-Dindo grade ≥III). The secondary endpoints were postoperative complications, specifically related to cirrhosis and pancreatic surgery, and survival for patients with pancreatic adenocarcinoma.
RESULTS: Overall, 32 patients with cirrhosis were matched with 128 patients without cirrhosis. Most patients (93.5%) had Child-Pugh A cirrhosis. The severe morbidity rate after distal pancreatectomy was higher in patients with cirrhosis than in those without cirrhosis (28.13% vs 25.75%, P = .11. The operative time was significantly longer in the cirrhotic group compared with controls (P = .01). However, patients with and without cirrhosis had comparable blood loss and conversion rates. Postoperatively, the two groups had similar rates of pancreatic fistula, hemorrhage, reoperation, postoperative mortality, and survival rates at 1, 3, and 5 years.
CONCLUSION: The current study suggests that distal pancreatectomy in high-volume centers is feasible for patients with compensated cirrhosis.
Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of "social time" to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles.
BACKGROUND: Benzodiazepines are the preferred treatment for alcohol withdrawal. Phenobarbital is an alternative in the setting of prescriber expertise or benzodiazepine contraindication.
OBJECTIVE: To evaluate the efficacy and safety of a phenobarbital dosing strategy aimed at treating a spectrum of alcohol withdrawal symptoms across various patient populations.
METHODS: Retrospective review of patients admitted with concerns of alcohol withdrawal between May 2018 and November 2022. Patients were separated into a before-after cohort of lorazepam or phenobarbital. The primary outcome was hospital length of stay (LOS). Secondary outcomes were intensive care unit (ICU) LOS, escalation of respiratory support, increased level of care (LOC), and incidence of delirium tremens and/or seizures.
RESULTS: Two hundred and seventy-seven patients received lorazepam and 198 received phenobarbital. Hospital LOS was longer in the phenobarbital cohort compared with the lorazepam cohort (6.9 vs 9.3 days). There was no difference in ICU LOS. Level of care increases were fewer in the phenobarbital cohort (4 events vs 19 events). There were higher rates of non-invasive respiratory interventions in the lorazepam cohort and higher rates of mechanical ventilation in the phenobarbital cohort. Utilization of phenobarbital was attributed to a reduction in delirium tremens and seizures.
CONCLUSION AND RELEVANCE: This study is novel because of the broad application of a phenobarbital order set across multiple levels of care and patient admission diagnoses. A risk targeted split load intravenous phenobarbital order set can safely be administered to patients with fewer escalations of care, seizures, delirium tremens, and respiratory care escalation.
Estrogen receptor α (ERα) is an important driver and therapeutic target in ∼70% of breast cancers. How ERα drives breast carcinogenesis is not fully understood. In this study, we show that ERα is a negative regulator of type I interferon (IFN) response. Activation of ERα by its natural ligand estradiol inhibits IFN-β-induced transcription of downstream IFN-stimulated genes (ISGs), whereas ERα deficiency or the stimulation with its antagonist fulvestrant has opposite effects. Mechanistically, ERα induces the expression of the histone 2A variant H2A.Z to restrict the engagement of the IFN-stimulated gene factor 3 (ISGF3) complex to the promoters of ISGs and also interacts with STAT2 to disrupt the assembly of the ISGF3 complex. These two events mutually lead to the inhibition of ISG transcription induced by type I IFNs. In a xenograft mouse model, fulvestrant enhances the ability of IFN-β to suppress ERα+ breast tumor growth. Consistently, clinical data analysis reveals that ERα+ breast cancer patients with higher levels of ISGs exhibit higher long-term survival rates. Taken together, our findings suggest that ERα inhibits type I IFN response via two distinct mechanisms to promote breast carcinogenesis.
For 4 weeks 20 session, this groups were applied hot pack with 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation(TENS) to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 Megahertz(MHz) and at a dosage of 1 w / cm2. Also, administered DTM to the back and neck region for 20 min in 12 sessions in addition to the conventional physical therapy.
A novel article of manufacture and the use thereof is provided herein. The article of manufacture includes packaging material and pharmaceutical agent contained within the packaging material. The pharmaceutical agent is therapeutically-effective for reducing or preventing nervous damage caused by traumatic metabolic, ischemic or hypoxic neural insult. The pharmaceutical agent is able to cross the blood-brain-barrier to contact the nervous tissue in a therapeutically-effective quantity. The pharmaceutical agent includes cyclosporin A or a compound of the class of cyclosporins, or functional derivatives, metabolites, variants or salts thereof, or combination of such compounds, either alone or in admixture with diluents, or additives. The packaging material comprises a label which indicates that the pharmaceutical agent can be used for reducing or preventing nervous damage caused by traumatic, metabolic, ischemic or hypoxic neural insult.
?The invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture. This invention requires construction of 3165-bp gene therapy DNA vector VTvaf17 for genetic modification of animal and human cells containing nucleotide sequence SEQ ID No. 1. The method of constructing 3165-bp gene therapy DNA vector VTvaf17 involves, first of all, constructing a 4182-bp vector that contains a 1188-bp promoter region of human elongation factor EF1A with an intrinsic enhancer, a 35-bp polylinker with sites for restriction endonucleases BamHI, EcoRV, Sail, Hindlll, Kpnl, EcoRI, a 466-bp transcription terminator and a polyadenylation sequence of the human growth factor, a 136-bp regulatory element RNA-OUT of transposon Tn10 allowing for antibiotic-free positive selection, a 1299-bp origin of replication for autonomous replication with a single nucleotide substitution to increase vector production in the cells of most Escherichia coli strains, a 1010-bp kanamycin resistance gene, and then it is cleaved by Spel restriction sites, and the remaining fragment is ligated to itself. The specified purpose is achieved by obtaining Escherichia coli strain SCS110-AF for the production of gene therapy DNA vector VTvaf17 or gene therapy DNA vectors based on it allowing for antibiotic-free positive selection. The method of obtaining Escherichia coli strain SCS110-AF for the production of gene therapy DNA vector VTvaf17 or gene therapy DNA vectors based on it involves constructing a 64-bp linear DNA fragment which contains regulatory element RNA-IN of transposon Tn10 allowing for antibiotic-free positive selection, 1422-bp levansucrase gene sacB the product of which ensures selection within a sucrose-containing medium, 763-bp chloramphenicol resistance gene catR required for the picking of strain clones in which homologous recombination occurs, and two homologous sequences, 329-bp and 233-bp, ensuring homologous recombination in the region of gene recA concurrent with gene inactivation, and then the Escherichia coli cells are transformed by electroporation, and clones surviving in a medium containing 10 µg/ml of chloramphenicol are picked. Escherichia coli strain SCS110-AF/VTvaf17 (registered at the Russian National Collection of Industrial Microorganisms under number B-12990, INTERNATIONAL DEPOSITARY AUTHORITY No. NCIMB 42801) carrying gene therapy DNA vector VTvaf17 is also constructed for its further development allowing for antibiotic-free selection. The method of obtaining Escherichia coli strain SCS110-AFA/Tvaf17 (registered at the Russian National Collection of Industrial Microorganisms under number B-12990, INTERNATIONAL DEPOSITARY AUTHORITY No. NCIMB 42801) carrying gene therapy DNA vector VTvaf17 involves making electrocompetent cells of Escherichia coli strain SCS110-AF and subjecting these cells to electroporation with gene therapy DNA vector VTvaf17. After that, the cells are poured into agar plates (Petri dishes) with a selective medium containing yeastrel, peptone, 6% sucrose, and 10 µg/ml of chloramphenicol.
FIELD: pharmacy. SUBSTANCE: described are products soluble within mouth cavity formed by pressing. They include granules comprising saccharide with low moldability and saccharide with high moldability. Products comprise active ingredient. Method comprises granulation of saccharide with low moldability with saccharide with high moldability followed by direct pressing of the resulting granules. Products are become rapidly decomposed and soluble in mouth cavity but are sufficiently hard not to be breakable throughout all stages of manufacture and distribution thereof. These properties make it possible for patients, especially children and elderly persons, to swallow them up easily. EFFECT: improved properties of the title products. 20 cl, 19 ex, 1 tbl
Patients with treatment-resistant depression constitute a significant proportion (even 30%) of patients diagnosed with major depressive disorder (MDD. Since 2014, there have been reports of a potential antidepressant effect of the R-ketamine stereoisomer. At the UCK Department of Psychiatry, a phase 2 clinical trial (2a) has been conducted since 2022 with the use of R-ketamine in the form of an intravenous solution, administered by an infusion pump to patients with drug-resistant depression (sponsor Perception Neuroscience, Inc., protocol PCN-101-21, NCT05414422). The available data from studies indicate a potential treatment-transformative effect of the drug, but do not provide comprehensive information on the long-term effects of treatment in terms of effectiveness, tolerability, and safety of R-ketamine use. The study is cognitive and comparative study, without interfering with the diagnostics, treatment, and rehabilitation. It aims to collect effectiveness and safety observations within 12 months of participation in the PCN-101-21 study, at quarterly intervals (3, 6, 9, 12 months, +/- 4 weeks), with particular emphasis on exacerbations of the underlying disease, hospitalization, correction of psychotropic treatment or functional impairment requiring support from social security authorities. The study does not involve additional diagnostic, therapeutic or rehabilitation goals and is a retrospective analysis performed during a single visit.